![]() |
|
|
Vol. 56, Issue 4, 834-840, October 1999
Department of Pharmacology and Toxicology, University of Louisville
School of Medicine, Louisville, Kentucky (Z.H.S.); Department of
Medical Pharmacology and Toxicology, Texas A&M University Health
Science Center, College Station, Texas (Z.H.S., C.-A.S.); and
Department of Chemistry, Kennesaw State University, Kennesaw, Georgia
(D.P.H., P.H.R.)
It has been reported that WIN55212-2, a prototypic aminoalkylindole,
has higher affinity for CB2 than for CB1. To
explain the selectivity of WIN55212-2 for CB2, molecular
modeling studies were performed to probe the interacting sites between
WIN55212-2 and cannabinoid receptors. In TMH5 the position 5.46 is a
Phe in CB2 versus a Val in CB1. Docking of
WIN55212-2 into the models of CB1 and CB2
predicts that F5.46 will result in a greater aromatic stacking of
CB2 with WIN55212-2. Using site-directed mutagenesis, this
hypothesis was tested by exchanging the amino acids at position 5.46 between CB1 and CB2. Two mutations, including a
Phe to Val mutation at the position 5.46 in CB2
(CB2F5.46V), and a corresponding Val to Phe mutation at the position
5.46 in CB1 (CB1V5.46F), were made. The mutant
receptors were transfected into 293 cells, and stable cell lines
expressing similar numbers of receptors as wild-type receptors were
chosen for additional ligand binding and cAMP accumulation studies. In
ligand- binding assays, the CB2F5.46V mutation decreased the affinity of WIN55212-2 for CB2 by 14-fold. In contrast,
the CB1V5.46F mutation increased the affinity of WIN55212-2
for CB1 by 12-fold. However, these mutations did not change
the affinity of HU-210, CP-55940, and anandamide for CB1
and CB2. In cAMP accumulation assays, the changes in
EC50 values of WIN55212-2 were consistent with the changes
in its binding affinity caused by the mutations. These results strongly
support the hypothesis that the selectivity of WIN55212-2 for
CB2 over CB1 is attributable to the change from Val in CB1 at position 5.46 to Phe in CB2.
This article has been cited by other articles:
![]() |
F. He, Z.-H. Qiao, J. Cai, W. Pierce, D.-C. He, and Z.-H. Song Involvement of the 90-kDa Heat Shock Protein (Hsp-90) in CB2 Cannabinoid Receptor-Mediated Cell Migration: A New Role of Hsp-90 in Migration Signaling of a G Protein-Coupled Receptor Mol. Pharmacol., November 1, 2007; 72(5): 1289 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Raduner, A. Majewska, J.-Z. Chen, X.-Q. Xie, J. Hamon, B. Faller, K.-H. Altmann, and J. Gertsch Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS J. Biol. Chem., May 19, 2006; 281(20): 14192 - 14206. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. F. Njie, A. Kumar, Z. Qiao, L. Zhong, and Z.-H. Song Noladin Ether Acts on Trabecular Meshwork Cannabinoid (CB1) Receptors to Enhance Aqueous Humor Outflow Facility Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1999 - 2005. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Lauckner, B. Hille, and K. Mackie The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins PNAS, December 27, 2005; 102(52): 19144 - 19149. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhong, L. Geng, Y. Njie, W. Feng, and Z.-H. Song CB2 Cannabinoid Receptors in Trabecular Meshwork Cells Mediate JWH015-Induced Enhancement of Aqueous Humor Outflow Facility Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 1988 - 1992. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF] |
||||